CN100490893C - 成骨组合物 - Google Patents

成骨组合物 Download PDF

Info

Publication number
CN100490893C
CN100490893C CNB200480005562XA CN200480005562A CN100490893C CN 100490893 C CN100490893 C CN 100490893C CN B200480005562X A CNB200480005562X A CN B200480005562XA CN 200480005562 A CN200480005562 A CN 200480005562A CN 100490893 C CN100490893 C CN 100490893C
Authority
CN
China
Prior art keywords
poly
rbmp
lactide
bmp
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200480005562XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1761481A (zh
Inventor
F·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN1761481A publication Critical patent/CN1761481A/zh
Application granted granted Critical
Publication of CN100490893C publication Critical patent/CN100490893C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB200480005562XA 2003-01-30 2004-01-29 成骨组合物 Expired - Fee Related CN100490893C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/354,856 2003-01-30
US10/354,856 US7074412B2 (en) 2003-01-30 2003-01-30 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
CN1761481A CN1761481A (zh) 2006-04-19
CN100490893C true CN100490893C (zh) 2009-05-27

Family

ID=32770436

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200480005562XA Expired - Fee Related CN100490893C (zh) 2003-01-30 2004-01-29 成骨组合物

Country Status (9)

Country Link
US (1) US7074412B2 (cg-RX-API-DMAC7.html)
EP (1) EP1589989A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006519782A (cg-RX-API-DMAC7.html)
KR (1) KR20050105446A (cg-RX-API-DMAC7.html)
CN (1) CN100490893C (cg-RX-API-DMAC7.html)
AU (1) AU2004208569B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407178A (cg-RX-API-DMAC7.html)
CA (1) CA2513712A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004067027A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7189409B2 (en) * 2004-03-09 2007-03-13 Inion Ltd. Bone grafting material, method and implant
US20060258578A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Pharmaceutical composition
KR100865759B1 (ko) * 2007-05-07 2008-10-29 울산대학교 산학협력단 사람의 골형성단백질-2를 암호화하는 유전자를 이용한 재조합된 사람의 골형성단백질-2의 제조방법
KR100932945B1 (ko) * 2009-01-16 2009-12-21 원광대학교산학협력단 골 분말과 피브린 글루로 이루어진 고형의 스캐폴드
KR100932948B1 (ko) * 2009-01-16 2009-12-21 원광대학교산학협력단 Ｂｍｐ-2를 함유하는 골 분말과 피브린 글루로 이루어진 고형의 스캐폴드
KR100932947B1 (ko) * 2009-01-16 2009-12-21 원광대학교산학협력단 안지오제닌을 함유하는 뼈 재생용 조성물
US8979534B2 (en) 2009-06-17 2015-03-17 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
US20150335400A1 (en) * 2009-06-17 2015-11-26 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
WO2012101173A1 (en) * 2011-01-26 2012-08-02 Universität Zürich N-methyl-2-pyrrolidone for prevention and treatment of bone loss
WO2017019832A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions using repair cells and cationic dyes
WO2017019833A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Compositions containing repair cells and cationic dyes
US12383246B2 (en) 2020-10-12 2025-08-12 Abbott Cardiovascular Systems, Inc. Vessel closure device with improved safety and tract hemostasis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP2002537022A (ja) * 1999-02-16 2002-11-05 ズルツァー バイオロジクス インコーポレイテッド 軟骨病変を再生して修復する装置及び方法
US6926903B2 (en) * 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant
US20030105530A1 (en) 2001-12-04 2003-06-05 Inion Ltd. Biodegradable implant and method for manufacturing one

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
preliminary in vivo studies on the osteogenic potential of bonemorphogenetic proteins delivered from an absorbable puttylikepolymer matrix. Andriano Kirk P et al.journal of biomedical materials research,Vol.53 . 2000 *

Also Published As

Publication number Publication date
AU2004208569B2 (en) 2008-07-31
WO2004067027A9 (en) 2004-10-07
BRPI0407178A (pt) 2006-02-07
CA2513712A1 (en) 2004-08-12
EP1589989A2 (en) 2005-11-02
KR20050105446A (ko) 2005-11-04
AU2004208569A1 (en) 2004-08-12
US7074412B2 (en) 2006-07-11
WO2004067027A3 (en) 2004-09-16
WO2004067027A2 (en) 2004-08-12
US20040152627A1 (en) 2004-08-05
JP2006519782A (ja) 2006-08-31
CN1761481A (zh) 2006-04-19

Similar Documents

Publication Publication Date Title
CN100490893C (zh) 成骨组合物
CA2085750C (en) Osteoinductive pharmaceutical formulations
Takahashi et al. Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel
EP1220693B1 (en) Formulations for delivery of osteogenic proteins
Kim et al. Guided bone regeneration using barrier membrane in dental applications
US6914050B2 (en) Stimulation of bone growth with thrombin peptide derivatives
CN105854074B (zh) 用于牵引成骨术的组合物和方法
Huber et al. Demineralized bone matrix as a carrier for bone morphogenetic protein-2: burst release combined with long-term binding and osteoinductive activity evaluated in vitro and in vivo
Félix Lanao et al. Porous calcium phosphate cement for alveolar bone regeneration
JP2020537590A (ja) 自家骨移植代替物
US11596712B2 (en) Autologous bone graft substitute composition
D'Albis et al. Use of hyaluronic acid for regeneration of maxillofacial bones
US20090291113A1 (en) Osteogenic composition comprising a growth factor, a soluble cation salt and organic support
JP2001131086A (ja) エンドセリンを含む結合組織修復促進組成物および該組成物の調製におけるエンドセリンの使用
Schrier et al. Effect of a freeze-dried CMC/PLGA microsphere matrix of rhBMP-2 on bone healing
Casap et al. Recombinant human bone morphogenetic protein-2 confined by an imperforate titanium shell over high-profile dental implants in rabbit tibiae: a pilot bone augmentation study.
US20100266691A1 (en) Agents and Methods to Stimulate Bone Healing
Allam et al. Evaluating The Biostimulation Effect Of Diode Laser 650 Nm Combined With TEMPO Oxidized Nano-Cellulose Mixed With Biphasic Tricalcium Phosphate On Bone Healing: Experimental Animal Study
EP1723961A2 (en) Pharmaceutical composition comprising at least one bone morphogenetic protein (BMP)
EP1475109A1 (en) Formulations for delivery of osteogenic proteins
Ekholm et al. The copolymer of ε-caprolactone-lactide and tricalcium phosphate does not enhance bone growth in mandibular defect of sheep
Zubaidah et al. BMP-7 expression after induction of hydroxyapatite bovine tooth graft gel as a socket preservation of the alveolar bone.
Kader et al. Recombinant human bone morphogenetic protein-2 versus autogenous bone graft in the reconstruction of maxillary anterior alveolar ridge defects
Gharah Bash EXPLORING SYNTHETIC LOW MOLECULAR WEIGHT HEPARINS FOR TREATMENT OF PERIODONTITIS
RU126590U1 (ru) Блок композитного материала для тканевой костной инженерии на основе костного недеминерализованного коллагена, содержащий фактор роста эндотелия сосудов

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090527

Termination date: 20100129